Search hospitals

>

Ontario

>

TORONTO

St. Michael's Hospital

Claim this profile

TORONTO, Ontario M5B 1W8

Global Leader in Breast Cancer

Global Leader in Heart Failure

Conducts research for Cardiovascular Disease

Conducts research for Heart Attack

Conducts research for Stroke

630 reported clinical trials

54 medical researchers

Photo of St. Michael's Hospital in TORONTOPhoto of St. Michael's Hospital in TORONTOPhoto of St. Michael's Hospital in TORONTO

Summary

St. Michael's Hospital is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, Heart Failure, Cardiovascular Disease, Heart Attack, Stroke and other specialties. St. Michael's Hospital is involved with conducting 630 clinical trials across 853 conditions. There are 54 research doctors associated with this hospital, such as Neil Fam, MD, Ron Wald, Amit Atrey, MD, and Sakina Rizvi, PhD.

Area of expertise

1

Breast Cancer

Global Leader

St. Michael's Hospital has run 40 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 positive
Stage IV
2

Heart Failure

Global Leader

St. Michael's Hospital has run 34 trials for Heart Failure. Some of their research focus areas include:

Stage II
Stage IV
Stage III

Top PIs

Clinical Trials running at St. Michael's Hospital

Heart Failure

Cancer

Cardiovascular Disease

Atrial Fibrillation

Suicide

Depression

Von Willebrand Disease

Respiratory Impairment

Stroke

Mastocytosis

Image of trial facility.

Stopping Heart Medications

for Cancer Survivors

Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in \>80% of patients. Unfortunately, heart failure medications are associated with an undesirable long-term pill burden, financial costs, and side-effects (e.g., dizziness and fatigue). As a result, cancer survivors frequently ask if they can safely stop their heart failure medications once their heart function has returned to normal. Currently there is no scientific evidence in this area of Cardio-Oncology. To address this knowledge gap, the investigators have designed a randomized control trial to assess the safety of stopping heart failure medication in patients with CTRCD and recovered heart function. The investigators will enrol patients who have completed their cancer therapy and are on heart medications for their CTRCD, which has now normalized. The investigators will randomize patients with no other reasons to continue heart failure medications (e.g., kidney disease) to continuing or stopping their heart medications safely. All patients will undergo a cardiac MRI at baseline, 1 and 5 years with safety assessments at 6-8 weeks, 6 months and 3 and 5 years. The investigators will determine if stopping medications is non-inferior to continuing medications by counting the numbers of patients who develop heart dysfunction by 1 year in each group.

Recruiting

3 awards

Phase 4

Image of trial facility.

Omecamtiv Mecarbil

for Heart Failure

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Recruiting

1 award

Phase 3

10 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at St. Michael's Hospital?

Where is St. Michael's Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does St. Michael's Hospital accept?

What awards or recognition has St. Michael's Hospital received?